¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ tcnO`0moK  
O9zMD8  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© $U. |  
+ kT ]qH  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© @87Y/_l  
:<bhQY  
1.Co-stimulators (or co-stimulating molecules) KO7&dM  
7G^Q2w  
2.NK-kB y2#"\5dC  
k7Qs#L  
3.Immunoglobulin superfamily 9)  ,|h  
#R:&Irh  
4.antigen-presenting cell (APC) +p6 3J  
(CRx'R  
5.death domain 4_iA<}>|  
AX$r,KmE  
6.CCR and CXCR ^\Z+Xq1~/  
eUZk|be  
7.Lectin (or mitogen) %cg | KB"l  
1++g @8  
8.Clusters of differentiation, CD) "^6Fh"]  
.MG83Si  
9.B7 family -e}(\  
lH`TF_  
10.Cytotoxic T lymphocyte, CTL) J<+ f7L  
!L9OJ1F  
11.IL-15 and IL-15 receptor (IL-15R) {pH#zs4Y  
~WTkX(\  
12.MHC restriction C0/^6Lu"o  
~a[ /l  
13.Affinity-chromatography z2t+1 In,  
 19]19_-  
14.Cyctosprin A, CsA pXl[I;  
/P@%{y  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ~`QoBZ.O&  
S}VS@KDO  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© P'OvwA  
FMeBsI9pL  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 El5} f4sl  
cbyzZ#WRb  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ @9KW ]7  
}' AY#g  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 Kus=.(  
aim\ 3y~  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© T8z?_ *k  
RSym9t90t  
ÃâÒßѧרҵ£º hk4t #Km  
( ~5 M{Xh  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ `9K5 ;]  
ZK^cG'^2|  
Ïû»¯ÄÚ¿Æ£º &R<aRE:+R  
X n!md R  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ -  /\qGI  
F,p0OL.  
ѪҺ²¡Ñ§×¨Òµ£º W[O]Aal{  
P+hcj p*  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»